1	64	{'label':'evaluation', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(0, 0), 'end':(0, 6), 'text':'RAF kinases regulate cell proliferation and survival'}, {'start':(0, 7), 'end':(0, 14), 'text':'and can be dysregulated in tumors , .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 12), 'text':'A role for RAF in cell proliferation has been linked to its ability'}, {'start':(1, 13), 'end':(1, 18), 'text':'to activate MEK and ERK .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 13), 'text':'Here , we identify a MEK independent role for RAF in tumor growth .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 11), 'text':'Specifically , in mitotic cells , CRAF becomes phosphorylated on serine 338'}, {'start':(3, 12), 'end':(3, 34), 'text':'and localizes to the mitotic spindle of proliferating tumor cells in vitro and in murine tumor models or biopsies from cancer patients .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 22), 'text':'Treatment of tumors with allosteric , but not ATP-competitive RAF inhibitors prevents CRAF phosphorylation on serine 338 , localization to the mitotic spindle'}, {'start':(4, 23), 'end':(4, 30), 'text':'and causes cell cycle arrest at pro-metaphase .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 21), 'text':'Furthermore , we identify phospho-S338 CRAF as a potential biomarker for tumor progression and a surrogate marker for allosteric RAF blockade .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 25), 'text':'Mechanistically , CRAF , but not BRAF associates with Aurora-A and Polo like kinase 1 at the centrosomes and spindle poles during G2 and Mitosis .'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 15), 'text':'Indeed , allosteric or genetic inhibition of phospho-S338 CRAF impairs Plk1 activation and accumulation at kinetochores'}, {'start':(7, 16), 'end':(7, 19), 'text':'causing pro-metaphase arrest ,'}]}, {'start':(7, 20), 'end':(7, 36), 'text':'while a phospho-mimetic S338D CRAF mutant potentiates Plk1 activation , mitosis and tumor progression in mice .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 16), 'text':'These findings reveal a previously undefined role for RAF in tumor progression beyond the RAF-MEK-ERK paradigm ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 17), 'end':(8, 19), 'text':'opening new avenues'}, {'start':(8, 20), 'end':(8, 25), 'text':'for targeting RAF in oncology .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 14), 'text':'ATP-competitive RAF inhibitors have shown clinical activity in cancers with activating RAF mutations - .'}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 6), 'text':'However , in RAS driven tumors ,'}, {'start':(10, 7), 'end':(10, 19), 'text':'these agents surprisingly promote CRAF serine 338 phosphorylation and tumor progression - .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 10), 'text':'We described an allosteric inhibitor of RAF ( compound 6 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 11), 'end':(11, 16), 'text':'referred to here as KG5 )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 17), 'end':(11, 22), 'text':'that does not compete for ATP'}, {'start':(11, 23), 'end':(11, 30), 'text':'but inhibits phospho-S338 CRAF and tumor growth .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 11), 'text':'KG5 exerted broad growth inhibitory activity against the NCI-60 panel ( )'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 12), 'end':(12, 12), 'text':'suggesting'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 13), 'end':(12, 18), 'text':'that KG5 influences a general mechanism'}, {'start':(12, 19), 'end':(12, 28), 'text':'that is independent of RAS or RAF activation status .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 1), 'text':'Tumor cells'}, {'start':(13, 2), 'end':(13, 4), 'text':'exposed to KG5'}]}, {'start':(13, 5), 'end':(13, 11), 'text':'appeared rounded and arrested in mitosis ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 12), 'end':(13, 13), 'text':'whereas cells'}, {'start':(13, 14), 'end':(13, 27), 'text':'treated with ATP-competitive RAF or MEK inhibitors maintained adhesion and mitosis ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 3), 'text':'KG5 inhibited phospho-S338 CRAF'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 4), 'end':(14, 8), 'text':'causing mitotic arrest at pro-metaphase'}, {'start':(14, 9), 'end':(14, 20), 'text':'followed by cell death in multiple tumor cell lines ( ) ,'}]}, {'start':(14, 21), 'end':(14, 26), 'text':'mimicking the effects of paclitaxel .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 6), 'text':'As for most kinase targeted drugs ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 7), 'end':(15, 10), 'text':'KG5 inhibits other targets'}, {'start':(15, 11), 'end':(15, 17), 'text':'( c-Kit , Flt-3 and PDGFR )'}]}, {'start':(15, 18), 'end':(15, 26), 'text':'that might contribute to the anti-proliferative effects observed .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(16, 0), 'end':(16, 3), 'text':'To address this ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 4), 'end':(16, 12), 'text':'we evaluated KG1 , a structural analogue of KG5'}, {'start':(16, 13), 'end':(16, 20), 'text':'that inhibits the same targets except RAF .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 6), 'text':'KG1 did not inhibit cell proliferation ,'}, {'start':(17, 7), 'end':(17, 19), 'text':'indicating the effects of KG5 are due to RAF inhibition ( ) .'}]}, {'start':(18, 0), 'end':(18, 15), 'text':'Phosphorylation of CRAF on serine 338 has been linked to cancer progression - , - .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(19, 0), 'end':(19, 10), 'text':'To determine whether KG5 could suppress this activity in vivo ,'}, {'start':(19, 11), 'end':(19, 30), 'text':'we analyzed orthotopic breast and brain tumor tissues for phospho-S338 CRAF before or after systemic delivery of the drug .'}]}, {'start':(20, 0), 'end':(20, 19), 'text':'A single KG5 treatment led to a qualitative decrease in phospho-S338 CRAF and an accumulation of cells at pro-metaphase .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(21, 0), 'end':(21, 1), 'text':'Importantly ,'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 2), 'end':(21, 18), 'text':'while ectopic expression of active MEK failed to rescue the effects of KG5 on cell proliferation ,'}, {'start':(21, 19), 'end':(21, 19), 'text':'cells'}]}, {'start':(21, 20), 'end':(21, 31), 'text':'expressing a phospho-mimetic S338D CRAF mutant showed resistance to KG5 ( )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 32), 'end':(21, 42), 'text':'suggesting CRAF S338 plays a MEK independent role in cell proliferation'}, {'start':(21, 43), 'end':(21, 51), 'text':'that can be reversed by an allosteric inhibitor .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 5), 'text':'We next examined mouse embryonic fibroblasts'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 6), 'end':(22, 8), 'text':'( MEFs )'}, {'start':(22, 9), 'end':(22, 19), 'text':'derived from CRAF knockout embryos ( Craf -/ - ) .'}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 20), 'text':'Asynchronized Craf -/ - MEFs showed a significant increase in the number of cells in G2 and M and pro-metaphase ,'}, {'start':(23, 21), 'end':(23, 28), 'text':'compared to wildtype ( WT ) MEFs .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 6), 'text':'Following synchronization , Craf -/ - MEFs'}, {'start':(24, 7), 'end':(24, 19), 'text':'accumulated in pro-metaphase with a dramatic delay in mitotic progression ( ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(25, 0), 'end':(25, 6), 'text':'Depletion of CRAF in tumor cells ,'}, {'start':(25, 7), 'end':(25, 20), 'text':'similarly led to an accumulation of cells in G2 and M ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 19), 'text':'Importantly , expression of kinase dead ( K375M ) , phospho-mimetic S338D or WT CRAF rescued this mitotic defect ,'}, {'label':'contrast', 'direction':'LeftToRight', 'children':[{'start':(26, 20), 'end':(26, 34), 'text':'whereas a non phosphorylatable ( S338A ) CRAF mutant , failed to do so ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(26, 35), 'end':(26, 41), 'text':'even though this mutant maintains kinase activity'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 42), 'end':(26, 46), 'text':'and can dimerize with BRAF'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 47), 'end':(26, 48), 'text':'( data'}, {'start':(26, 49), 'end':(26, 52), 'text':'not shown ) .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 6), 'text':'Accordingly , XPA-1 human pancreatic cancer cells'}, {'start':(27, 7), 'end':(27, 14), 'text':'expressing WT CRAF completed mitosis in twenty minutes'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 15), 'end':(27, 16), 'text':'whereas cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 17), 'end':(27, 29), 'text':'expressing CRAF S338A did so in 120 minutes ( ) providing genetic evidence'}, {'start':(27, 30), 'end':(27, 41), 'text':'to support a kinase independent role for phospho-S338 CRAF in mitosis .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 8), 'text':'Furthermore , phospho-S338 CRAF was strongly increased in mitosis'}, {'start':(28, 9), 'end':(28, 43), 'text':'where it co-precipitated with gamma-tubulin ( ) and localized in G2 and M to the centrosomes and mitotic spindle poles of tumor cells in vitro , or breast cancer tissues from mice or patients .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(29, 0), 'end':(29, 15), 'text':'Importantly , KG5 , but not ATP-competitive RAF inhibitors , prevented this localization ( ) .'}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 3), 'text':'Moreover , in cells'}, {'start':(30, 4), 'end':(30, 11), 'text':'treated with the microtubule stabilizing agent paclitaxel ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 12), 'end':(30, 18), 'text':'CRAF remained localized to the mitotic spindle'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(30, 19), 'end':(30, 19), 'text':'suggesting'}, {'start':(30, 20), 'end':(30, 33), 'text':'that KG5 and paclitaxel arrest cells at pro-metaphase via distinct mechanisms ( ) .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(31, 0), 'end':(31, 3), 'text':'Previous studies have revealed'}, {'label':'joint', 'direction':'None', 'children':[{'start':(31, 4), 'end':(31, 10), 'text':'that CRAF and BRAF can form heterodimers'}, {'start':(31, 11), 'end':(31, 21), 'text':'and that BRAF can play a role in mitosis - .'}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(32, 0), 'end':(32, 1), 'text':'Interestingly ,'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(32, 2), 'end':(32, 13), 'text':'while BRAF and CRAF heterodimers could readily be detected in asynchronized cells'}, {'start':(32, 14), 'end':(32, 25), 'text':'we could not detect such heterodimers in mitotic cells ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 11), 'text':'In fact , phospho-S338 CRAF localized to the spindle pole in cells'}, {'start':(33, 12), 'end':(33, 16), 'text':'lacking BRAF ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(34, 0), 'end':(34, 2), 'text':'These results suggest'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 3), 'end':(34, 5), 'text':'that the role'}, {'start':(34, 6), 'end':(34, 17), 'text':'that CRAF plays in mitosis is distinct from that of BRAF .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(35, 0), 'end':(35, 17), 'text':'Mitosis is regulated by various mitotic kinases such as Aurora kinases , Plk1 , and CDK1 - .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(36, 0), 'end':(36, 7), 'text':'Plk1 becomes activated by Aurora-A in G2 ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(36, 8), 'end':(36, 13), 'text':'localizes to centrosomes , spindle poles'}, {'start':(36, 14), 'end':(36, 22), 'text':'and accumulates at kinetochores at pro-metaphase- ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(37, 0), 'end':(37, 3), 'text':'Accordingly , tumor cells'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(37, 4), 'end':(37, 6), 'text':'expressing oncogenic RAS'}, {'label':'joint', 'direction':'None', 'children':[{'start':(37, 7), 'end':(37, 19), 'text':'are particularly dependent on Plk1 activity for mitotic progression and survival , ,'}, {'start':(37, 20), 'end':(37, 36), 'text':'and inhibition or depletion of Plk1 causes cell cycle delay and arrest at pro-metaphase , - .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 31), 'text':'Interestingly , both Aurora-A and Plk1 co-precipitated with CRAF but not BRAF and CRAF co-localized with Aurora-A and Plk1 at the centrosomes in G2 and spindle poles in mitotic tumor cells .'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 7), 'text':'Interestingly , CRAF , but not BRAF ,'}, {'start':(39, 8), 'end':(39, 12), 'text':'co-precipitated with Plk1 ( )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 13), 'end':(39, 19), 'text':'and this could be detected in cells'}, {'start':(39, 20), 'end':(39, 31), 'text':'expressing WT or kinase dead ( K375M ) CRAF ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 8), 'text':'However , this complex was minimally detected in cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 9), 'end':(40, 15), 'text':'expressing the S338A RAF mutant ( )'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(40, 16), 'end':(40, 16), 'text':'suggesting'}, {'start':(40, 17), 'end':(40, 32), 'text':'that the interaction between CRAF and Plk1 requires serine 338 phosphorylation but not kinase activity .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 0), 'end':(41, 7), 'text':'Thus , CRAF may serve as a scaffold'}, {'start':(41, 8), 'end':(41, 17), 'text':'bringing Aurora-A and Plk1 into a functional mitotic complex .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(42, 0), 'end':(42, 18), 'text':'To determine whether the kinetics of CRAF serine 338 phosphorylation during cell cycle progression correlated with Plk1 activation ,'}, {'start':(42, 19), 'end':(42, 37), 'text':'we analyzed CRAF ( S338 ) and Plk1 ( T210 ) phosphorylation throughout the cell cycle from G1-M .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 9), 'text':'Interestingly , phospho-S338 CRAF levels were increased in G1 ,'}, {'start':(43, 10), 'end':(43, 12), 'text':'as expected ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 13), 'end':(43, 36), 'text':'but showed a second wave of phosphorylation at G2 and M beginning immediately prior to Plk1 phosphorylation ( ) , consistent with the notion'}, {'start':(43, 37), 'end':(43, 46), 'text':'that CRAF phosphorylation on serine 338 precedes Plk1 activation .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 18), 'text':'To further explore a role for CRAF in Plk1 activation , lysates from WT and Craf -/ - MEFs'}, {'start':(44, 19), 'end':(44, 31), 'text':'were subjected to immunoblotting for phospho-Plk1 or evaluated for Plk1 enzymatic activity .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 9), 'text':'Indeed , Craf -/ - MEFs demonstrated minimal Plk1 activity'}, {'start':(45, 10), 'end':(45, 14), 'text':'compared to WT MEFs .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(46, 0), 'end':(46, 3), 'text':'Furthermore , tumor cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 4), 'end':(46, 12), 'text':'arrested in pro-metaphase with KG5 showed decreased Plk1 activity'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 13), 'end':(46, 15), 'text':'compared to cells'}, {'start':(46, 16), 'end':(46, 23), 'text':'arrested with nocodazole or paclitaxel ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(47, 0), 'end':(47, 16), 'text':'While treatment of cells with KG5 had no effect on Plk1 localization to the spindle pole ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 17), 'end':(47, 39), 'text':'it prevented the subsequent accumulation of active Plk1 at the kinetochores ( ) and similar findings were observed in Craf -/ - MEFs'}, {'start':(47, 40), 'end':(47, 42), 'text':'( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(48, 0), 'end':(48, 3), 'text':'These findings were substantiated'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 4), 'end':(48, 18), 'text':'since an active form of Plk1 was able to rescue the G2 and M delay'}, {'start':(48, 19), 'end':(48, 25), 'text':'caused by CRAF depletion ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(49, 0), 'end':(49, 4), 'text':'Together , these results indicate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 5), 'end':(49, 11), 'text':'that CRAF potentiates Plk1 or Aurora-A activation'}, {'start':(49, 12), 'end':(49, 21), 'text':'leading to accumulation of active Plk1 at the kinetochores .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(50, 0), 'end':(50, 6), 'text':'This process facilitates mitotic progression through pro-metaphase'}, {'start':(50, 7), 'end':(50, 20), 'text':'and can be blocked by inhibition of phospho-S338 CRAF via allosteric RAF blockade .'}]}]}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(51, 0), 'end':(51, 14), 'text':'To investigate the impact of the CRAF and Plk1 signaling module in tumor progression ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 15), 'end':(51, 27), 'text':'we evaluated the tumor growth capacity of human colon carcinoma and glioblastoma cells'}, {'start':(51, 28), 'end':(51, 35), 'text':'stably expressing the phospho-mimetic S338D CRAF mutant .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 2), 'text':'HCT-116 colon cells'}, {'start':(52, 3), 'end':(52, 8), 'text':'expressing the S338D CRAF mutant showed'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 9), 'end':(52, 20), 'text':'accelerated mitosis and a significant increase in tumor growth relative to cells'}, {'start':(52, 21), 'end':(52, 40), 'text':'expressing WT CRAF and this was associated with increased phospho-Plk1 but not phospho-MEK expression in these tumors ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 4), 'text':'Similarly , U-87 glioblastoma cells'}, {'start':(53, 5), 'end':(53, 7), 'text':'expressing S338D CRAF'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 8), 'end':(53, 18), 'text':'produced a significant increase in brain tumor growth relative to cells'}, {'start':(53, 19), 'end':(53, 24), 'text':'expressing WT CRAF ( ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 2), 'text':'Furthermore , cells'}, {'start':(54, 3), 'end':(54, 14), 'text':'expressing a double mutant S338D kinase dead ( S338D and K375M )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 15), 'end':(54, 24), 'text':'also showed increase Plk1 activity and tumor growth in mice'}, {'start':(54, 25), 'end':(54, 32), 'text':'but failed to activate MEK ( ) .'}]}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(55, 0), 'end':(55, 2), 'text':'These results demonstrate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 3), 'end':(55, 12), 'text':'that phospho-S338 CRAF is an important mediator of tumor progression'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 13), 'end':(55, 16), 'text':'based on its capacity'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 17), 'end':(55, 22), 'text':'to promote mitosis in a manner'}, {'start':(55, 23), 'end':(55, 29), 'text':'that is independent of active MEK .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 11), 'text':'While RAF is an essential component of the canonical MAPK signaling pathway'}, {'start':(56, 12), 'end':(56, 14), 'text':'various reports reveal'}]}, {'start':(56, 15), 'end':(56, 21), 'text':'that RAF exerts kinase independent functions ,'}]}, {'start':(56, 22), 'end':(56, 23), 'text':'- .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(57, 0), 'end':(57, 2), 'text':'We previously showed'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(57, 3), 'end':(57, 11), 'text':'that CRAF , independent of its kinase activity ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(57, 12), 'end':(57, 16), 'text':'could translocate to the mitochondria'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(57, 17), 'end':(57, 21), 'text':'and protect cells from apoptosis'}, {'start':(57, 22), 'end':(57, 29), 'text':'by inhibiting the pro-apoptotic protein ASK1 , .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(58, 0), 'end':(58, 12), 'text':'Here , we reveal a kinase independent function of CRAF in cell proliferation'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(58, 13), 'end':(58, 14), 'text':'and demonstrate'}, {'label':'joint', 'direction':'None', 'children':[{'start':(58, 15), 'end':(58, 20), 'text':'that phospho-S338 CRAF localizes to centrosomes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(58, 21), 'end':(58, 29), 'text':'and mitotic spindle poles in G2 and M ,'}, {'start':(58, 30), 'end':(58, 49), 'text':'where it interacts with Aurora-A and Plk1 , promotes Plk1 activation and thereby mitotic and tumor progression ( ) .'}]}]}]}]}]}]}]}, {'start':(59, 0), 'end':(59, 16), 'text':'Whether CRAF interaction with Aurora-A and Plk1 is direct or indirect still needs to be determined .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 6), 'text':'However , these data support the conclusion'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(60, 7), 'end':(60, 14), 'text':'that CRAF may act as an adaptor protein'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 15), 'end':(60, 20), 'text':'to promote Aurora-A or Plk1 activation'}, {'start':(60, 21), 'end':(60, 26), 'text':'facilitating mitosis and tumor progression .'}]}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 0), 'end':(61, 8), 'text':'While our findings may be relevant to all cells'}, {'start':(61, 9), 'end':(61, 11), 'text':'undergoing mitosis ,'}]}, {'start':(61, 12), 'end':(61, 22), 'text':'targeting this pathway with allosteric RAF inhibitors , like KG5 ,'}]}, {'start':(61, 23), 'end':(61, 32), 'text':'might be particularly effective during angiogenesis and tumor growth ,'}]}, {'start':(61, 33), 'end':(61, 39), 'text':'processes characterized by highly proliferative cells .'}]}]}]}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(62, 0), 'end':(62, 4), 'text':'Finally , our studies reveal'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 5), 'end':(62, 7), 'text':'that allosteric inhibitors'}, {'start':(62, 8), 'end':(62, 22), 'text':'designed to block phospho-S338 CRAF and its function in mitosis represent a new therapeutic approach'}]}, {'start':(62, 23), 'end':(62, 33), 'text':'to inhibit the growth of a wide range of cancers .'}]}]}]}
64	66	{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Methods'}, {'start':(1, 0), 'end':(1, 16), 'text':'Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/ .'}]}
0	1	{'start':(0, 0), 'end':(0, 10), 'text':'A MEK independent role for CRAF in mitosis and tumor progression'}
67	68	{'start':(0, 0), 'end':(0, 0), 'text':'1'}
66	67	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
